Skip to main content
  1. Shami PJ, Saavedra JA, Wang LY, Bonifant C, Diwan B, Buzard G, Keefer LK. JS-K, a Glutathione S-Transferase Activated Nitric Oxide Donor with Potent Anti-neoplastic Activity. Molecular Cancer Therapeutics. 2:409-417, 2003.
  2. Elenitoba-Johnson KSJ, Jenson SD, Abbott RT, Palais RA, Bohling SD, Lin Z, Tripp S, Shami PJ, Wang LY, Coupland RW, Buckstein B, Perez-Ordonez B, Perkins SL, Lim MS. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci U S A. 100(12):7259-64,2003.
  3. Saavedra JE, Srinivasan A, Buzard GS, Davies, KM, Waterhouse DJ, Inami K, Wilde TC, Citro ML, Cuellar M, Deschamps JR, Parrish D, Shami PJ, Findlay VJ, Townsend DM, Tew KD, Singh S, Jia L, Ji X,  Keefer LK. PABA/NO as an Anticancer Lead: Analogue Synthesis, Structure Revision, Solution Chemistry, Reactivity toward Glutathione, and In Vitro Activity. Journal of Medicinal Chemistry. 49(3):1157-1164,2006.
  4. Shami PJ, Saavedra JE, Bonifant CL, Chu J, Udupi V, Malaviya S, Carr BI, Kar S, Wang M, Jia L, JiX, Keefer LK. Antitumor Activity of JS-K and Related O2-Aryl Diazeniumdiolates In Vitro and In Vivo. Journal of Medicinal Chemistry 49(14):4356-4366,2006.
  5. Udupi V, Yu M, Malaviya S, Saavedra JE, Shami PJ. JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells. Leukemia Research 30(10):1279-1283,2006.
  6. Kiziltepe T, Hideshima T, Ishitsuka K, Raje N, Li CQ, Trudel LJ, Yasui H, Catley L, Ocio EM, Tai YT, Coffey R, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GN, Keefer LK, Shami PJ, Anderson KC. JS-K, a GST-activated nitric oxide generator, induces DNA double strand breaks, activates DNA damage response pathways, and induces apoptosis in human multiple myeloma cells. Blood 110(2):709-18,2007.
  7. Chakrapani H, Goodblatt MM, Udupi V, Malaviya S, Shami PJ, Keefer LK, and Saavedra JE. Synthesis and In Vitro Anti-Leukemic Activity of Structural Analogues of JS-K, an Anti-Cancer Lead Compound. Bioorganic and Medicinal Chemistry Letters 18:950-953, 2008.
  8. Nandurdikar RS, Maciag AE, Citro ML, Shami PJ, Keefer LK, Saavedra JE, Chakrapani H. Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound. Bioorganic & Medicinal Chemistry Letters 19:2760-2,2009.
  9. Liu J, Tari A, Saavedra JE, Keefer LK, Tokar E, Sun Y, Waalkes MP, Shami PJ. Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells. Genomics 94:32–38,2009.
  10. Shami PJ, Eddington JK, Udupi V, Maciag A, Kosak KM, Saavedra JE, Keefer LK. JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C). Leukemia Research 33:1525-1529,2009.
  11. Kiziltepe T, Anderson KC, Kutok JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami PJ. JS-K has Potent Anti-Angiogenic Activity In Vitro and Inhibits Tumor Angiogenesis in a Multiple Myeloma Model In Vivo. Journal of Pharmacy and Pharmacology 62:145-151,2010.
  12. HM, Erba HP, Claxton D, Arellano M, Craig M, Douer D, Gabrilove J, Lyons R, Kovascovics T, Maris M, Petersdorf S, Shami PJ, Yaeger A, Eckert S, Abichandani R, Faderl S, On behalf of the CLASSIC II Investigators. Phase II Study of Clofarabine Induction and Consolidation Therapy In Previously Untreated Older Adults With Acute Myelogenous Leukemia for Whom Conventional Induction Chemotherapy is Unlikely to be of Benefit Due to Unfavorable Baseline Risk Factors. Journal of Clinical Oncology 28:549-555), 2010.
  13. Edes K, Cassidy P, Shami PJ, Moos PJ. JS-K, a Nitric Oxide Prodrug, Has Enhanced Cytotoxicity in Colon Cancer Cells with Knockdown of Thioredoxin Reductase 1. PLoS One. 20;5(1):e8786, 2010.
  14. Maciag AE, Chakrapani H, Saavedra JE, Morris NL, Holland RJ, Kosak KM, Shami PJ, Anderson LM and Keefer LK. The diazeniumdiolate-based nitric oxide-releasing prodrug JS-K is effective against non-small cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species. Journal of Pharmacy and Experimental Therapeutics 336(2):313-20, 2011.
  15. Maciag AE, Nandurdikar RS , Hong SY, Chakrapani H, Diwan B, Morris NL, Shami PJ, Anderson LM , Keefer LK and Saavedra JE. Activation of the c-Jun N-terminal kinase /ATF3 pathway characterizes effective diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs (JS-K class). Journal of Medicinal Chemistry 54(22):7751-8, 2011.
  16. Weidensteiner C, Reichardt W, Shami PJ, Saavedra JE, Keefer LK, Baumer B, Werres A, Jasinski R, Osterberg N, Weyerbrock A. Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI. Nitric Oxide 30:17-25, 2013.
  17. Kaur I, Terrazas M, Kosak KM, Kern SE, Boucher KM, Shami PJ. Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug JS-K, formulated in Pluronic® P123 micelles. Journal of Pharmacy and Pharmacology 65(9):1329-36, 2013.